Surrozen Inc SEC Filings

Surrozen, Inc. (SRZN) reported insider buying by investment funds affiliated with The Column Group. Multiple Column Group limited partnerships, each a 10% owner, disclosed open‑market purchases of Surrozen common stock on January 15, 16 and 20, 2026.

Examples include The Column Group III, LP buying 5,590 shares at $19.889 and 8,484 shares at $19.5999, and The Column Group III-A, LP buying 6,303 shares at $19.889 and 9,568 shares at $19.5999. Following these purchases, The Column Group III, LP reported beneficial ownership of 900,292 shares, The Column Group III-A, LP reported 1,016,658 shares, and The Column Group Opportunity III, LP reported holding 344,827 shares.

The filing notes that general partners and managing partners associated with these funds may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.

Surrozen, Inc. director and 10% owner Tim Kutzkey reported indirect open‑market purchases of the company’s common stock by investment funds he helps manage. Between January 15 and January 20, 2026, The Column Group III, LP and The Column Group III-A, LP bought a total of 32,507 shares at prices around $19.60–$20.00 per share. After these transactions, The Column Group III, LP held 900,292 shares, The Column Group III-A, LP held 1,016,658 shares, and The Column Group Opportunity III, LP held 344,827 shares, all reported as indirectly beneficially owned. The general partners and managing partners, including Kutzkey, disclaim beneficial ownership except to the extent of their pecuniary interest.

Surrozen, Inc. director and 10% owner Tim Kutzkey reported indirect open‑market purchases of the company’s common stock by investment funds he helps manage. Between January 15 and January 20, 2026, The Column Group III, LP and The Column Group III-A, LP bought a total of 32,507 shares at prices around $19.60–$20.00 per share. After these transactions, The Column Group III, LP held 900,292 shares, The Column Group III-A, LP held 1,016,658 shares, and The Column Group Opportunity III, LP held 344,827 shares, all reported as indirectly beneficially owned. The general partners and managing partners, including Kutzkey, disclaim beneficial ownership except to the extent of their pecuniary interest.

Surrozen, Inc. entered into a Sales Agreement with TD Securities (USA) LLC (referred to as TD Cowen) that allows the company to sell, from time to time, up to $50.0 million of its common stock through an at-the-market offering. TD Cowen will act as sales agent and/or principal and use commercially reasonable efforts to execute sales based on Surrozen’s instructions, including price, timing, and size parameters. Surrozen will pay TD Cowen a commission of up to 3.0% of the gross sales proceeds for any shares sold, and either party can terminate the agreement by written notice. Any sales will be made under Surrozen’s existing Form S-3 shelf registration, using a base prospectus and an August 29, 2025 prospectus supplement.

Surrozen, Inc. discloses a high-risk development-stage profile: the company has a history of operating losses and expects to continue incurring significant losses while none of its product candidates have regulatory approval. The filing emphasizes substantial funding needs to advance its Wnt therapeutics pipeline and acknowledges that future equity or debt financings could dilute existing shareholders. It lists multiple outstanding and reserved equity instruments, including 8,499,821 shares (or pre-funded warrants) offered at $11.60 per share in a March 2025 private placement and several classes of warrants and options exercisable at specified prices.

The company also details material operational risks: reliance on third parties for trials and manufacturing, potential clinical delays or safety setbacks, competitive pressures, international regulatory and trade risks, and concentrated stockholder voting control that may limit minority influence.

Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 455,299 shares of Surrozen, Inc. common stock (CUSIP 86889P208), representing 5.18% of the outstanding class as of June 30, 2025. The reported total includes 225,772 shares that may be acquired within 60 days upon exercise of warrants. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross jointly report beneficial ownership of 1,016,197 shares of Surrozen common stock, representing 11.4% of the class. That total comprises 686,539 currently outstanding shares and 329,658 shares issuable upon exercise of warrants. The Reporting Persons disclose no sole voting or dispositive power; they report shared voting power of 963,133 and shared dispositive power of 1,016,197.

The 11.4% figure is calculated using a base of 8,562,584 shares outstanding plus certain warrants added pursuant to Rule 13d-3(d)(1)(i), including Series E Warrants and 2024 PIPE Series A and B warrants. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Driehaus Capital Management LLC reports beneficial ownership of 67,566 shares of Surrozen, Inc. common stock, equal to 0.79% of the class. The filing shows Driehaus has shared voting and shared dispositive power over all 67,566 shares and reports no sole voting or dispositive power. The filer is identified as an investment adviser (IA). Item 5 is marked for ownership of 5 percent or less of a class, and Items 6-9 indicate no holdings on behalf of others, no parent/subsidiary acquisition, and no group affiliation.

Surrozen, Inc. is the issuer and this Schedule 13G/A discloses that Stonepine-related reporting persons collectively beneficially own 508,687 shares of Surrozen common stock, representing 5.8% of the outstanding class. That total is composed of 306,029 shares of Common Stock plus 202,658 shares issuable on exercise of Series A, B and E warrants, with the calculation based on 8,570,355 shares outstanding as reported by the issuer.

The reporting persons (Stonepine Capital Management, LLC; Stonepine Capital, L.P.; Stonepine GP, LLC; and Jon M. Plexico) report shared voting and dispositive power over the 508,687 shares and no sole voting or dispositive power. The partnership holds the shares for investors and may direct receipt of dividends or sale proceeds. The filing includes a certification that the position was not acquired to change or influence control of the issuer.

Surrozen, Inc. registers 250,000 shares of its common stock, par value $0.0001 per share, to be issued under the Surrozen, Inc. 2025 Equity Inducement Plan. The registration statement incorporates the company’s prior annual, proxy, quarterly and current reports by reference so that those documents form part of the disclosure for the plan.

The filing reiterates that the company provides contractual indemnification to directors and officers under Delaware law, maintains indemnification agreements and standard directors-and-officers insurance, and includes the 2025 Plan and related legal and auditor consents as exhibits.

Surrozen reported a cash position of $90.4 million and returned a net income of $39.7 million for the three months ended June 30, 2025, and $12.8 million for the six‑month period, driven largely by noncash fair‑value changes in a tranche liability and warrant liabilities. Operating activities used $15.4 million of cash in the first half of 2025 while the company recorded a consolidated accumulated deficit of approximately $272.5 million. In March 2025 Surrozen completed the first tranche of a two‑tranche private placement (the 2025 PIPE), raising net proceeds of about $71.2 million from the first closing and issuing 5.2 million shares, pre‑funded warrants and Series E warrants; the second tranche is contingent on FDA clearance of an IND for SZN‑8141. Warrant liabilities and a remaining tranche liability create significant noncash volatility: warrant liabilities were reported at $32.6 million and the tranche liability at $10.9 million as of June 30, 2025. Management believes existing cash is sufficient for at least 12 months, but the company expects continued R&D spending and may need additional capital to advance its pipeline.